Finally, HER2 and HER3 were co-expressed in 11% and HER3 alone in 27% of the 45 pancreatic ductal adenocarcinomas analyzed by immunohistochemistry. This evidence concerns the gene ERBB2 and pancreatic ductal adenocarcinoma.